Dr Melani Shares Impressive Results of the ViPOR Trial for MCL

from Oncology Learning Network · host HMP Global

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Episode metadata supplied by the publisher feed · Published Feb 2, 2022

Embed this episode

Attribution link and audio player

Ready to play

Dr Melani Shares Impressive Results of the ViPOR Trial for MCL

0:00 8:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 8 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on February 2, 2022.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!